{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,25]],"date-time":"2026-09-25T08:05:55Z","timestamp":1790323555607,"version":"4.1.0"},"reference-count":25,"publisher":"BMJ","issue":"1","content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["j. immunotherapy cancer"],"published-print":{"date-parts":[[2019,12]]},"DOI":"10.1186\/s40425-019-0533-0","type":"journal-article","created":{"date-parts":[[2019,3,4]],"date-time":"2019-03-04T08:03:35Z","timestamp":1551686615000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":40,"title":["Exceptional response and multisystem autoimmune-like toxicities associated with the same T cell clone in a patient with uveal melanoma treated with immune checkpoint inhibitors"],"prefix":"10.1136","volume":"7","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-1389-925X","authenticated-orcid":false,"given":"Suthee","family":"Rapisuwon","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Benjamin","family":"Izar","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Cory","family":"Batenchuk","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alexandre","family":"Avila","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shaolin","family":"Mei","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Peter","family":"Sorger","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jerry M.","family":"Parks","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sarah J.","family":"Cooper","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David","family":"Wagner","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jay C.","family":"Zeck","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Aline J.","family":"Charabaty","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michael B.","family":"Atkins","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"239","published-online":{"date-parts":[[2019,3,4]]},"reference":[{"key":"533_CR1","doi-asserted-by":"crossref","first-page":"251","DOI":"10.1023\/A:1023684502638","volume":"14","author":"PD Inskip","year":"2003","unstructured":"Inskip PD, Devesa SS, Fraumeni JF Jr. Trends in the incidence of ocular melanoma in the United States, 1974-1998. Cancer Causes Control. 2003;14:251\u20137.","journal-title":"Cancer Causes Control"},{"key":"533_CR2","doi-asserted-by":"crossref","first-page":"1681","DOI":"10.1016\/j.cell.2015.05.044","volume":"161","author":"Cancer Genome Atlas N","year":"2015","unstructured":"Cancer Genome Atlas N. Genomic classification of cutaneous melanoma. Cell. 2015;161:1681\u201396.","journal-title":"Cell"},{"key":"533_CR3","doi-asserted-by":"crossref","first-page":"56","DOI":"10.1126\/science.aaa8172","volume":"348","author":"P Sharma","year":"2015","unstructured":"Sharma P, Allison JP. The future of immune checkpoint therapy. Science. 2015;348:56\u201361.","journal-title":"Science"},{"key":"533_CR4","doi-asserted-by":"crossref","first-page":"23","DOI":"10.1056\/NEJMoa1504030","volume":"373","author":"J Larkin","year":"2015","unstructured":"Larkin J, Chiarion-Sileni V, Gonzalez R, Grob JJ, Cowey CL, Lao CD, Schadendorf D, Dummer R, Smylie M, Rutkowski P, et al. Combined Nivolumab and Ipilimumab or monotherapy in untreated melanoma. N Engl J Med. 2015;373:23\u201334.","journal-title":"N Engl J Med"},{"key":"533_CR5","doi-asserted-by":"crossref","first-page":"3344","DOI":"10.1002\/cncr.30258","volume":"122","author":"AP Algazi","year":"2016","unstructured":"Algazi AP, Tsai KK, Shoushtari AN, Munhoz RR, Eroglu Z, Piulats JM, Ott PA, Johnson DB, Hwang J, Daud AI, et al. Clinical outcomes in metastatic uveal melanoma treated with PD-1 and PD-L1 antibodies. Cancer. 2016;122:3344\u201353.","journal-title":"Cancer"},{"key":"533_CR6","doi-asserted-by":"crossref","first-page":"3687","DOI":"10.1002\/cncr.28282","volume":"119","author":"JJ Luke","year":"2013","unstructured":"Luke JJ, Callahan MK, Postow MA, Romano E, Ramaiya N, Bluth M, Giobbie-Hurder A, Lawrence DP, Ibrahim N, Ott PA, et al. Clinical activity of ipilimumab for metastatic uveal melanoma: a retrospective review of the Dana-Farber Cancer Institute, Massachusetts General Hospital, Memorial Sloan-Kettering Cancer Center, and University Hospital of Lausanne experience. Cancer. 2013;119:3687\u201395.","journal-title":"Cancer"},{"issue":"suppl; abstr 95","key":"533_CR7","first-page":"2017","volume":"35","author":"JM Piulats","year":"2017","unstructured":"Piulats JM, De La Cruz-Merino L, Curiel Garcia MT, Berrocal A, Alonso-Carri\u00f3n L, Espinosa E, L\u00f3pez Castro R, Rodriguez-Abreu D, Luna Fra P, Martin-Algarra S. Phase II multicenter, single arm, open label study of nivolumab (NIVO) in combination with ipilimumab (IPI) as first line in adult patients (pts) with metastatic uveal melanoma (MUM): GEM1402 NCT02626962. J Clin Oncol. 2017;35(suppl; abstr 9533):2017.","journal-title":"J Clin Oncol"},{"key":"533_CR8","doi-asserted-by":"crossref","first-page":"204","DOI":"10.1016\/j.ccell.2017.07.003","volume":"32","author":"AG Robertson","year":"2017","unstructured":"Robertson AG, Shih J, Yau C, Gibb EA, Oba J, Mungall KL, Hess JM, Uzunangelov V, Walter V, Danilova L, et al. Integrative analysis identifies four molecular and clinical subsets in uveal melanoma. Cancer Cell. 2017;32:204\u201320 e215.","journal-title":"Cancer Cell"},{"key":"533_CR9","doi-asserted-by":"crossref","first-page":"1109","DOI":"10.1056\/NEJMp1607591","volume":"375","author":"RL Grossman","year":"2016","unstructured":"Grossman RL, Heath AP, Ferretti V, Varmus HE, Lowy DR, Kibbe WA, Staudt LM. Toward a shared vision for cancer genomic data. N Engl J Med. 2016;375:1109\u201312.","journal-title":"N Engl J Med"},{"key":"533_CR10","doi-asserted-by":"crossref","first-page":"773","DOI":"10.1200\/JCO.2014.57.4756","volume":"33","author":"HE Teulings","year":"2015","unstructured":"Teulings HE, Limpens J, Jansen SN, Zwinderman AH, Reitsma JB, Spuls PI, Luiten RM. Vitiligo-like depigmentation in patients with stage III-IV melanoma receiving immunotherapy and its association with survival: a systematic review and meta-analysis. J Clin Oncol. 2015;33:773\u201381.","journal-title":"J Clin Oncol"},{"key":"533_CR11","doi-asserted-by":"crossref","first-page":"1410","DOI":"10.1126\/science.1194472","volume":"330","author":"JW Harbour","year":"2010","unstructured":"Harbour JW, Onken MD, Roberson ED, Duan S, Cao L, Worley LA, Council ML, Matatall KA, Helms C, Bowcock AM. Frequent mutation of BAP1 in metastasizing uveal melanomas. Science. 2010;330:1410\u20133.","journal-title":"Science"},{"key":"533_CR12","doi-asserted-by":"crossref","first-page":"415","DOI":"10.1038\/nature12477","volume":"500","author":"LB Alexandrov","year":"2013","unstructured":"Alexandrov LB, Nik-Zainal S, Wedge DC, Aparicio SA, Behjati S, Biankin AV, Bignell GR, Bolli N, Borg A, Borresen-Dale AL, et al. Signatures of mutational processes in human cancer. Nature. 2013;500:415\u201321.","journal-title":"Nature"},{"key":"533_CR13","doi-asserted-by":"crossref","first-page":"2930","DOI":"10.1172\/JCI91190","volume":"127","author":"M Ayers","year":"2017","unstructured":"Ayers M, Lunceford J, Nebozhyn M, Murphy E, Loboda A, Kaufman DR, Albright A, Cheng JD, Kang SP, Shankaran V, et al. IFN-gamma-related mRNA profile predicts clinical response to PD-1 blockade. J Clin Invest. 2017;127:2930\u201340.","journal-title":"J Clin Invest"},{"key":"533_CR14","doi-asserted-by":"crossref","first-page":"8390","DOI":"10.1038\/ncomms9390","volume":"6","author":"JR Lin","year":"2015","unstructured":"Lin JR, Fallahi-Sichani M, Sorger PK. Highly multiplexed imaging of single cells using a high-throughput cyclic immunofluorescence method. Nat Commun. 2015;6:8390.","journal-title":"Nat Commun"},{"key":"533_CR15","doi-asserted-by":"crossref","first-page":"568","DOI":"10.1038\/nature13954","volume":"515","author":"PC Tumeh","year":"2014","unstructured":"Tumeh PC, Harview CL, Yearley JH, Shintaku IP, Taylor EJ, Robert L, Chmielowski B, Spasic M, Henry G, Ciobanu V, et al. PD-1 blockade induces responses by inhibiting adaptive immune resistance. Nature. 2014;515:568\u201371.","journal-title":"Nature"},{"key":"533_CR16","doi-asserted-by":"crossref","first-page":"511","DOI":"10.1093\/bioinformatics\/btv639","volume":"32","author":"M Andreatta","year":"2016","unstructured":"Andreatta M, Nielsen M. Gapped sequence alignment using artificial neural networks: application to the MHC class I system. Bioinformatics. 2016;32:511\u20137.","journal-title":"Bioinformatics"},{"key":"533_CR17","doi-asserted-by":"crossref","first-page":"33","DOI":"10.1186\/s13073-016-0288-x","volume":"8","author":"M Nielsen","year":"2016","unstructured":"Nielsen M, Andreatta M. NetMHCpan-3.0; improved prediction of binding to MHC class I molecules integrating information from multiple receptor and peptide length datasets. Genome Med. 2016;8:33.","journal-title":"Genome Med"},{"key":"533_CR18","doi-asserted-by":"crossref","first-page":"77","DOI":"10.1097\/CJI.0000000000000154","volume":"40","author":"M Bricout","year":"2017","unstructured":"Bricout M, Petre A, Amini-Adle M, Bezza W, Seve P, Kodjikian L, Dalle S, Thomas L. Vogt-Koyanagi-Harada-like syndrome complicating Pembrolizumab treatment for metastatic melanoma. J Immunother. 2017;40:77\u201382.","journal-title":"J Immunother"},{"key":"533_CR19","doi-asserted-by":"crossref","first-page":"540","DOI":"10.1055\/s-0042-102668","volume":"233","author":"FC Fierz","year":"2016","unstructured":"Fierz FC, Meier F, Chaloupka K, Boni C. Intraocular inflammation associated with new therapies for cutaneous melanoma - case series and review. Klin Monatsbl Augenheilkd. 2016;233:540\u20134.","journal-title":"Klin Monatsbl Augenheilkd"},{"key":"533_CR20","doi-asserted-by":"crossref","first-page":"965","DOI":"10.1001\/jamaophthalmol.2015.1128","volume":"133","author":"D Mantopoulos","year":"2015","unstructured":"Mantopoulos D, Kendra KL, Letson AD, Cebulla CM. Bilateral Choroidopathy and serous retinal detachments during Ipilimumab treatment for cutaneous melanoma. JAMA Ophthalmol. 2015;133:965\u20137.","journal-title":"JAMA Ophthalmol"},{"key":"533_CR21","doi-asserted-by":"crossref","first-page":"928","DOI":"10.3928\/23258160-20171030-09","volume":"48","author":"MT Witmer","year":"2017","unstructured":"Witmer MT. Treatment of ipilimumab-induced Vogt-Koyanagi-Harada syndrome with oral dexamethasone. Ophthalmic Surg Lasers Imaging Retina. 2017;48:928\u201331.","journal-title":"Ophthalmic Surg Lasers Imaging Retina"},{"key":"533_CR22","doi-asserted-by":"crossref","first-page":"688","DOI":"10.1038\/nm.3883","volume":"21","author":"CO Park","year":"2015","unstructured":"Park CO, Kupper TS. The emerging role of resident memory T cells in protective immunity and inflammatory disease. Nat Med. 2015;21:688\u201397.","journal-title":"Nat Med"},{"key":"533_CR23","doi-asserted-by":"crossref","unstructured":"Chan PY, Hall P, Hay G, Cohen VML, Szlosarek PW. A major responder to ipilimumab and nivolumab in metastatic uveal melanoma with concomitant autoimmunity. Pigment Cell Melanoma Res. 2017;30:558\u201362.","DOI":"10.1111\/pcmr.12607"},{"key":"533_CR24","doi-asserted-by":"crossref","first-page":"883","DOI":"10.2217\/imt.12.85","volume":"4","author":"LP McLean","year":"2012","unstructured":"McLean LP, Shea-Donohue T, Cross RK. Vedolizumab for the treatment of ulcerative colitis and Crohn's disease. Immunotherapy. 2012;4:883\u201398.","journal-title":"Immunotherapy"},{"key":"533_CR25","doi-asserted-by":"crossref","first-page":"1749","DOI":"10.1056\/NEJMoa1609214","volume":"375","author":"DB Johnson","year":"2016","unstructured":"Johnson DB, Balko JM, Compton ML, Chalkias S, Gorham J, Xu Y, Hicks M, Puzanov I, Alexander MR, Bloomer TL, et al. Fulminant myocarditis with combination immune checkpoint blockade. N Engl J Med. 2016;375:1749\u201355.","journal-title":"N Engl J Med"}],"container-title":["Journal for ImmunoTherapy of Cancer"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1186\/s40425-019-0533-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2020,11,28]],"date-time":"2020-11-28T23:28:31Z","timestamp":1606606111000},"score":1,"resource":{"primary":{"URL":"https:\/\/jitc.bmj.com\/lookup\/doi\/10.1186\/s40425-019-0533-0"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,3,4]]},"references-count":25,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2019,12]]}},"alternative-id":["533"],"URL":"https:\/\/doi.org\/10.1186\/s40425-019-0533-0","relation":{},"ISSN":["2051-1426"],"issn-type":[{"value":"2051-1426","type":"electronic"}],"subject":[],"published":{"date-parts":[[2019,3,4]]},"assertion":[{"value":"25 October 2018","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"11 February 2019","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"4 March 2019","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"Not Applicable.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Consent for a special study and publication was obtained from the patient.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors declare that they have no competing interests.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}},{"value":"Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Publisher\u2019s Note"}}],"article-number":"61"}}